Clinical Studies I

A. Blood Lipid Lowering Activity and Related Effects

Study 1

Phase II Clinical Studies conducted in India as shown below:-

Figure 16
Effect of Gugulipid on serum cholesterol levels of hyperlipidemic patients.


Figure 17
Effect of Gugulipid on the serum lipids of 7 patients with ischemic heart disease.

Figure 18
Effect of Gugulipid on serum lipids of 39 patients without ischemic heart disease.


Figure 19
Effect of Gugulipid on the HDL, LDL, and VLDL of patients without IHD.


Figure 20
Effect of Gugulipid on the HDL, LDL, and VLDL of patients with IHD.


Figure 21
Effect of Gugulipid on the serum cholesterol levels of hyperlipidemic patients.

 

"These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, cure, or prevent any disease"
 

Copyright © Sabinsa Corporation. All Rights Reserved | Disclaimer

Disclaimer
×

US-FDA: This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Usage disclaimer: The information pertaining to any marketing materials by Sabinsa, is for general purposes only. Users are urged to check the validity of patents if any, on any Sabinsa items for their intended use.

EFSA: This statement has not been evaluated by the EFSA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Australia: Please note as an ingredient supplier the information contained in this website is for marketers of finished products formulations and is not intended as consumer advice. Marketers should ensure finished products are lawful and comply with the regulations of the countries in which these items are sold. Every care has been taken to ensure the accuracy of the information provided at the time of publication.